Sphingosine Kinase Inhibitors via Substrate Binding Site Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds that inhibit sphingosine kinases have low potency, lack selectivity for SphK1 or SphK2, and are not metabolically stable, making them unsuitable for effectively addressing sphingosine kinase-mediated disease states.
Innovation Solution
Development of novel compounds, such as (S)-2-(3-(4-octylphenyl)-1,2,4-oxadiazol-5-yl)pyrrolidine-1-carboximidamide, which act as selective inhibitors of SphK1 or SphK2 enzymes, competing with sphingosine rather than ATP, thereby inhibiting the sphingosine substrate-binding domain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current sphingosine kinase inhibitors are used, then some inhibitory activity is achieved, but potency is low and selectivity for SphK1 or SphK2 is lacking
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features (amidine or amidine-like groups) that target particular regions of the sphingosine kinase active site. This localized molecular design enables selective binding to either SphK1 or SphK2, improving both potency and enzyme-specific selectivity rather than generic inhibition
Solution Approach 2:
The patent employs parameter changes by modifying key molecular parameters of the inhibitors including the introduction of amidine functional groups, optimization of hydrophobic interactions through specific substituent patterns, and adjustment of molecular geometry. These parameter optimizations transform weak inhibitors into potent, selective agents with nanomolar IC50 values
2Reliability
If current sphingosine kinase inhibitors are used, then some inhibition is achieved, but metabolic stability is poor
Solution Approach 1:
The patent applies the taking out principle by removing metabolically labile functional groups from the inhibitor structures and replacing them with metabolically stable amidine or amidine-like groups. This extraction of unstable elements while retaining the core inhibitory pharmacophore improves metabolic stability without sacrificing inhibitory potency
Solution Approach 2:
The patent employs composite materials by combining metabolically stable amidine core structures with various hydrophobic and hydrophilic substituent groups. This composite molecular design creates inhibitors that resist metabolic degradation while maintaining optimal binding affinity and pharmacological activity
3Reliability
If inhibitors targeting ATP binding site are used, then kinase inhibition is achieved, but selectivity among different kinases is reduced
Solution Approach 1:
The patent applies inversion by reversing the conventional kinase inhibition strategy. Instead of targeting the conserved ATP binding site (which leads to broad kinase inhibition), the inhibitors are designed to target the sphingosine substrate binding region, which exhibits greater variability between SphK1 and SphK2. This inverted targeting approach enables selective inhibition while maintaining potent kinase activity blockade
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate enhanced potency, selectivity, and bioavailability, effectively inhibiting SphK enzymes, offering potential therapeutic benefits in treating diseases related to inflammation, angiogenesis, and vascular growth.
Implementation Method 1
competing with sphingosine rather than ATP, thereby inhibiting the sphingosine substrate-binding domain
Data Source
Figure 1a~1e
Figure 2a~2c
Figure 3a~3b
AI summary
The invention relates to inhibitors of sphingosine kinase enzymatic activity, compounds and pharmaceutical compositions that inhibit sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) enzymes and further relates to methods of treating diseases and disorders mediated by sphingosine 1 phosphate activity, comprising administering an effective amount of sphingosine kinase inhibitors.